Jinling Hospital
Nanjing, Jiangsu, 210000, China
NCT Number: NCT06908005
Patients with suspected Lung cancer who underwent contrast-enhanced CT and pathological examinations at Center 1 between January 2011 and January 2020 and Center 2 between September 2017 and Januray 2020 were eligible for inclusion in this study.The Clinical data, preoperative clinical information, laboratory results, CT images and pathological sections were collected. The investigators also collected the disease-free survival and overall survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and PyRadiomics was used to extract the radiomic features. Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software. The investigators developed RaFIST, a radiomics-based stratification tool, to noninvasively quantify intratumoral fibrosis in non-small cell lung cancer (NSCLC) using contrast-enhanced CT imaging. And it was further tested on the held-out external test cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nanjing, Jiangsu, 210000, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Radiomic features of tumor tissue
Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software (v1.5)
Time frame: Record from the date of surgery to the date of recurrence or death from any cause, whichever comes first, and assess up to a maximum of 5 years.
DFS was defined as the duration from the date of primary surgery to the first occurrence of recurrence or death from any cause.
Time frame: Record from the date of surgery to the date of death from any cause,whichever comes first, and assess up to a maximum of 5 years.
Jinling Hospital, China
Other
Development and Prognostic Validation of RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06737367
Bronchial Neoplasms, Carcinoma, Bronchogenic
Nanjing, China
View Trial DetailsNCT06621147
Bronchial Neoplasms, Carcinoma, Bronchogenic
View Trial DetailsNCT07405190
Bronchial Neoplasms, Carcinoma, Bronchogenic
Boston, Massachusetts, United States
View Trial DetailsNCT07216209
Behavior, Bronchial Neoplasms
Tucson, Arizona, United States
View Trial Details